Cell Therapy and Technology

Cell Therapy and Technology (CTT) is a South Korean biotechnology company specializing in the development of next-generation chimeric antigen receptor (CAR) T-cell therapies for hematological and solid tumors. Operating as a strategic subsidiary of AbClon, the company utilizes the proprietary "zCAR-T" and "Switchable CAR-T" platforms, which are designed to enhance the safety, precision, and control of immune cell activity. CTT's lead clinical asset, AT101 (also known as CTT-501), is a CD19-targeted CAR-T therapy currently in Phase 2 clinical trials for relapsed or refractory B-cell lymphoma. The company's pipeline also includes innovative candidates targeting HER2 for gastric and ovarian cancers, as well as Mesothelin-targeted therapies for solid tumors. By leveraging its parent company's antibody discovery expertise, CTT focuses on developing novel binders that differentiate its therapies from existing first-generation CAR-T products. The company is headquartered in Seoul and maintains dedicated GMP manufacturing capabilities for clinical-stage cell processing.